Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Thursday that the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01) of IBI354.
The trial is evaluating Innovent's IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. IBI354 has two pivotal Phase 3 trials ongoing (HeriCare-Ovarian01 and HeriCare-Breast01), with the potential to deliver a new generation of ADC therapies characterised by high potency and low toxicity.
HeriCare-Breast01 is a multicentre, randomised, open-label, active-controlled study designed to evaluate the safety and efficacy of IBI354, with or without pertuzumab, compared with the current standard-of-care, paclitaxel plus trastuzumab and pertuzumab (THP). The primary endpoint is progression-free survival.
AstraZeneca reports positive Phase III results for BREZTRI in uncontrolled asthma
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Akeso's AK139 Phase II clinical trials approved in China
Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris
Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit
AsymBio builds integrated platforms across biopharmaceutical development lifecycle
Evogene expands Google Cloud collaboration to integrate AI agents into ChemPass AI
Cumulus Neuroscience enters Japanese market with Shionogi collaboration
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1